Navigation Links
OSI Pharmaceuticals Announces Pivotal Phase III Tarceva Study,Published in the Journal of Clinical Oncology Showed Survival,Improvement in Patients with Pancreatic Cancer

Safety Profile

There have been infrequent reports of serious Interstitial Lung Disease (ILD)-like events, including fatalities, in patients receiving Tarceva for treatment of NSCLC, pancreatic cancer, or other advanced solid tumors. In the pancreatic cancer trial, other serious adverse events associated with Tarceva, and which may have included fatalities, were myocardial infarction/ischemia, cerebrovascular accident, and microangiopathic hemolytic anemia with thrombocytopenia. The most common side effects in patients with pancreatic cancer receiving Tarceva (100 mg) plus gemcitabine were fatigue, rash, nausea, anorexia, and diarrhea. Severe rash (5%) and severe diarrhea (5%) each resulted in dose reductions in 2% of patients, and discontinuation in up to 1% of patients. The most common side effects in patients with NSCLC receiving Tarceva monotherapy (150 mg) were mild to moderate rash (9%) and diarrhea (6%) which resulted in 1% of Tarceva-treated patients discontinuing therapy. When receiving Tarceva therapy, women should be advised against becoming pregnant or breastfeeding.

About OSI Pharmaceuticals

OSI Pharmaceuticals is committed to "shaping medicine and changing lives" by discovering, developing and commercializing high-quality and novel pharmaceutical products designed to extend life and/or improve the quality of life for patients with cancer and diabetes/obesity. The Company's oncology programs are focused on developing molecular targeted therapies designed to change the paradigm of cancer care. OSI's diabetes/obesity efforts are committed to the generation of novel, targeted therapies for the treatment of type 2 diabetes and obesity. OSI's flagship product, Tarceva(R) (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have demonstrated the ability to improve survival in both non-small cell lung cancer and pancreatic cancer patients in certain settings. OSI markets Tarcev
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:6/18/2013)... 2013  Healthgrades, the leading online resource that ... physicians and hospitals, today issued the Healthgrades ... Healthcare Decisions to Get Your Best Outcome . The ... maternity care, gynecologic surgery, as well as hospitals ... 15 of the most common hospital-based conditions and ...
(Date:6/18/2013)... , June 18, 2013  Isis Pharmaceuticals, Inc. (NASDAQ: ... announced that management will present a general corporate update in ... House on Tuesday, June 25 at 2:10 p.m. Pacific Time ... agenda for the meeting is as follows: 2:00 p.m. – ... record as of April 26, 2013) 2:10 p.m. – 3:15 ...
(Date:6/17/2013)... 17, 2013 DNAtrix Inc., experts in oncolytic ... clinical data on the company,s lead product, DNX-2401, at ... Quebec City, Canada on June 18, 2013. ... and a leader in the field of oncolytic virus ... A PHASE I TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS ...
Breaking Medicine Technology:Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 2Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 3Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 4Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House 2DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus 2
... Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) and the ... have entered into a research collaboration to enable more ... cancer. The collaboration is based on ... specific spliced viral RNA molecules (i.e., RNA markers) in ...
... SEATTLE, Oct. 8 Throughout October, National Breast Cancer ... and its clinical care partner, the Seattle Cancer Care ... sheets regarding a variety of topics related to breast ... treatment, and survivorship. The series will conclude Friday, Oct. ...
Cached Medicine Technology:Roche and German Cancer Research Center (DKFZ) Enter Research Agreement to Predict Cervical Cancer 2Roche and German Cancer Research Center (DKFZ) Enter Research Agreement to Predict Cervical Cancer 310 Tips for Breast Cancer Screening and Early Detection 210 Tips for Breast Cancer Screening and Early Detection 310 Tips for Breast Cancer Screening and Early Detection 4
(Date:6/19/2013)... US Drug Watchdog says, “We have discovered a ... a recipient of a DePuy Pinnacle metal on metal hip ... and chromium, because we believe this the best way short ... the event the cobalt, or chromium levels are elevated we ... to consider, including possible revision surgery to replace the device, ...
(Date:6/19/2013)... National Camp Series (NCS) Associate ... The Dream’s effort to fight ovarian cancer according to NFL ... "We are excited to have Dan jump on board,” says ... young specialists; great example, great purpose. That is exactly what ... Zeidman says Kicking For The Dream is definitely ...
(Date:6/18/2013)... Los Angeles, CA (PRWEB) June 19, 2013 ... field of bariatric surgery, are holding complimentary weight loss ... dates, the detailed program can be accessed at their ... that minimizes surgery and recovery time. Their highly skilled ... approach to bariatric surgery. , A senior executive ...
(Date:6/18/2013)... 19, 2013 Parker Waichman LLP, a ... victims injured by dangerous drugs and medical devices, has ... who alleges that she was injured by transvaginal ... 30th in the U.S. District Court for the Southern ... the multidistrict litigation entitled In Re: American Medical Systems, ...
(Date:6/18/2013)... As obesity rates sky rocket in the ... equipment during childbirth comes as no shock. Forceps are surgical ... when she is unable to do so herself and although ... higher rates of complication for both the mother and the ... mother and child, forceps births add to the pressure of ...
Breaking Medicine News(10 mins):Health News:US Drug Watchdog Now Urges Recipients Of A DePuy Pinnacle All Metal Hip Implant To Call Them About A Vital Blood Test To See If Their Hip Implant Device Has Failed 2Health News:National Camp Series (NCS) Associate Dan Zeidman of Lifetime Kicking Academy Joins Kicking For The Dream’s Effort to Fight Ovarian Cancer 2Health News:National Camp Series (NCS) Associate Dan Zeidman of Lifetime Kicking Academy Joins Kicking For The Dream’s Effort to Fight Ovarian Cancer 3Health News:oBand Surgery Centers Will Hold Complimentary Weight Loss Seminars in Los Angeles in June 2Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 2Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 3Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 4Health News:Forceps Births Double, Obesity is Major Reason in Births Complications 2
... The holiday season can be a time full of joy, ... those recovering from an eating disorder, it,s a time of ... uncertain future. Family gatherings with a loved one in recovery ... , "In my practice, I have even seen ...
... , SAN FRANCISCO, Nov. 24 ... and services provider, announced today that it has licensed ... of Michigan for integration into Quantros, suite of safety ... software within the SRM product family will enable automated ...
... , LAKE SUCCESS, N.Y., Nov. 24 ... certification, an international quality management standard focused on ... improving business performance. Certification to ISO 9001:2008 ... Management System (QMS) has passed a rigorous external ...
... sedatives, antidepressants, benzodiazepines, review finds , TUESDAY, Nov. ... sedatives and other psychotropic medications may be at ... , Canadian researchers analyzed 22 published studies that ... 60. The studies evaluated nine classes of drugs: ...
... Pa., Nov. 24 Governor Edward G. Rendell today ... were vaccinated during the weekend at public health clinics ... departments. , "With the federal government unable to ... H1N1 vaccine, distribution has been challenging," said Governor Rendell. ...
... While the holiday season often brings families and friends ... difficult for those grieving the death of a loved one. ... families. The holiday season can bring additional challenges to those ... for Grieving Children, Adolescents and Their Families, is available for ...
Cached Medicine News:Health News:When Holiday Meals Aren't a Gift 2Health News:When Holiday Meals Aren't a Gift 3Health News:Quantros Licenses Adverse Event Identification Technology from University of Michigan 2Health News:Quantros Licenses Adverse Event Identification Technology from University of Michigan 3Health News:IPRO Earns Third Consecutive Quality Management Certification 2Health News:Some Prescription Meds May Raise Seniors' Risks of Falling 2Health News:Governor Rendell Announces 100,000 At-Risk Pennsylvanians Vaccinated at H1N1 Public Health Clinics; Addresses Future Vaccine Distribution Plans 2Health News:Highmark Caring Place Resources Help Children and Families Who Are Grieving During the Holidays 2
For restriction digests, immuno-precipitations, enzyme assays, TLC spotting and others...
The Ultra Micro tip for the Eppendorf and Nichiryo/BenchMate 0.5-10 L pipettors is perfect for working with low volume samples....
... The easy way to order tips. Each ... tips)except for D10mL, which contains 200 tips (4 ... re-sealable Bulk Packs of 200 tips per pack. ... which can easily be opened for quick access ...
... The economical way to order tips. Each ... 1000 tips). Also available in easy-to-open, re-sealable ... Bulk Packs are sealed with a tamper-proof ... quick access to Gilsons Diamond Tips. Bulk ...
Medicine Products: